Skip to main content

Table 3 Clinician-reported health information

From: Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients

  Total (N = 15)
n (%)
Menopausal status
 Pre-menopausal 3 (20.0%)
  Not on gonadotropin-releasing hormone (GnRH) agonist treatment 3 (100.0%)
 Post-menopausal 12 (80.0%)
Mammalian target of rapamycin (mTOR) inhibitor treatment
 Yes 3 (20.0%)
 No 12 (80.0%)
Recurrent or progressive disease refractory to non-steroidal aromatase inhibitor (NSAI), tamoxifen, or fulvestrant
 Yes 6 (40.0%)
 No 9 (60.0%)
Eastern Cooperative Oncology Group (ECOG) score
 0 1 (6.7%)
 1 11 (73.3%)
 2 3 (20.0%)
Cyclin-dependent kinase (CDK4/6) inhibitor treatment
 Yes 5 (33.3%)
 No 10 (66.7%)
Metastatic sitea
 Bone 13 (86.7%)
 Lung 2 (13.3%)
 Liver 3 (20.0%)
 Lymph node 1 (6.7%)
 Skin 1 (6.7%)
  1. aNot mutually exclusive